Biogen stock gains after Piper Sandler lifts target to USD 245
Published on 09/04/2026 at 12:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Biogen Inc. (US09062X1037) stock is trading against a fresh analyst update: Piper Sandler raised its price target to USD 245 from USD 225 on September 3, 2026, while keeping an Overweight rating. Investing.com said the shares traded at USD 221.94 and were near the 52-week high of USD 225.59.
Analyst target moves higher
The target increase matters because it came with a concrete valuation change of 8.89 percent and a share price that was only USD 3.65 below the quoted 52-week high. GuruFocus also cited a current price of USD 224.20 and a market capitalization of about USD 33.13 billion.
For investors, that leaves the chart close to the top of its range while the fundamental backdrop is still anchored in the latest reported quarter. Biogen reported second-quarter 2026 revenue of USD 2.74 billion and adjusted EPS of USD 3.60, which topped the consensus figures of USD 2.46 billion and USD 2.94.
Q2 numbers still matter
The same second-quarter 2026 release also shows how sharp the earnings beat was: adjusted EPS came in USD 0.66 above consensus, a 22.4 percent surprise versus the estimate. Yahoo Finance also lists the next-quarter EPS estimate at USD 2.18 for September 2026, with full-year 2026 EPS estimates at USD 12.46.
That combination of a higher target, a near-high share price and a still-strong quarterly beat keeps the stock tied to expectations for pipeline execution rather than only to one-day trading noise. The number that surprises most is the 77.38 percent EPS surprise in the June 30, 2026 quarter on Yahoo Finance.
Leqembi stays relevant
Biogen's product story still runs through Leqembi. Finance Yahoo reported on September 3, 2026 that Biogen and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, available in the U.S. for initiation and maintenance therapy.
That gives the company a concrete commercial reference point beyond analyst notes: the drug launch is current, the quarter is current, and the stock is trading close to its recent peak.
Stock near its range
Biogen stock was quoted at USD 221.94 on September 3, 2026, with a 52-week high of USD 225.59. The stock data and the latest quarterly numbers put the September 4, 2026 setup in a narrow band near the top of the range.
Leqembi launch drive
LEQEMBI IQLIK is the representative product in the current Biogen story. The launch links the company's neurology franchise to the latest analyst debate, because the market is now pricing both pipeline momentum and commercial execution.
Biogen stock on the screen
Biogen stock is quoted at USD 221.94 as of September 3, 2026, with a 52-week high of USD 225.59 and a market capitalization of about USD 33.13 billion. Those figures place the shares near the top of the recent trading range as of September 4, 2026.
Biogen at a glance
- Company: Biogen Inc.
- ISIN: US09062X1037
- Ticker: BIIB
- Trading venue: NASDAQ
- Price (as of September 3, 2026): USD 221.94
- Market capitalization: USD 33.13 billion (as of September 3, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: S&P 500
